Microbot Medical (FRA:CY9D) Accounts Payable: €0.94 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:CY9D Microbot Medical Inc FRA:CY9D
37 GF Score
Price €1.50
! 2 Warning Signs
View Full Analysis

What is Microbot Medical Accounts Payable?

Microbot Medical FRA:CY9D +7.94% 37 Accounts Payable is €0.94 Mil as of Mar. 2026. GuruFocus rates FRA:CY9D with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Microbot Medical's Accounts Payable for the quarter that ended in Mar. 2026 was €0.94 Mil.

Microbot Medical's quarterly Accounts Payable increased from Sep. 2025 (€0.43 Mil) to Dec. 2025 (€0.44 Mil) and increased from Dec. 2025 (€0.44 Mil) to Mar. 2026 (€0.94 Mil).

Microbot Medical's annual Accounts Payable declined from Dec. 2023 (€0.33 Mil) to Dec. 2024 (€0.16 Mil) but then increased from Dec. 2024 (€0.16 Mil) to Dec. 2025 (€0.44 Mil).

Microbot Medical Accounts Payable Related Terms

Microbot Medical Accounts Payable Historical Data

* Premium members only.

The historical data trend for Microbot Medical's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbot Medical Accounts Payable Chart

Microbot Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.11 0.33 0.16 0.44

Microbot Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.44 0.43 0.44 0.94
FRA:CY9D
37GF Score
Microbot Medical Inc FRA:CY9D
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Microbot Medical Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €0.94 Mil mean?
Microbot Medical (FRA:CY9D) has a Accounts Payable of €0.94 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Microbot Medical and its competitors.
Is Microbot Medical's Accounts Payable too high?
Microbot Medical's current Accounts Payable is €0.94 Mil. Overall, Microbot Medical has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's Accounts Payable compare to STXS and DXR?
Microbot Medical's Accounts Payable of €0.94 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Microbot Medical and its competitors. Microbot Medical's current Accounts Payable is €0.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (FRA:CY9D) has a current Accounts Payable of €0.94 Mil. The current Accounts Payable is €0.94 Mil. Microbot Medical's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Microbot Medical (FRA:CY9D), the current Accounts Payable is €0.94 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microbot Medical Business Description

Other Exchanges MBOT:USA
Address 175 Derby Street, Building 27, Hingham, MA, USA, 02043
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
37GF Score

Get the complete analysis for FRA:CY9D

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.50
Price